Medpace downgraded by Jefferies with a new price target
$MEDP
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Jefferies downgraded Medpace from Buy to Hold and set a new price target of $345.00 from $415.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | Outperform → Mkt Perform | William Blair | |
| 4/14/2025 | $328.00 | Buy → Hold | TD Cowen |
| 3/24/2025 | $330.00 | Market Perform | Leerink Partners |
| 10/23/2024 | $413.00 → $349.00 | Outperform → Neutral | Robert W. Baird |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/27/2024 | $420.00 → $350.00 | Buy → Neutral | UBS |
| 9/25/2024 | $415.00 → $345.00 | Buy → Hold | Jefferies |
| 8/1/2024 | $415.00 | Hold | Truist |
William Blair downgraded Medpace from Outperform to Mkt Perform
TD Cowen downgraded Medpace from Buy to Hold and set a new price target of $328.00
Leerink Partners initiated coverage of Medpace with a rating of Market Perform and set a new price target of $330.00